CORE--IMAGING

核心--成像

• 批准号: 7700619
• 负责人: DAVID A. BLUEMKE
• 金额: $ 34.03万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7700619
• 关键词: Biological Markers; Blood Vessels; Cardiac; Cardiovascular Physiology; Cardiovascular system; Data; Deterioration; Disease; Disease Marker; Echocardiography; Evaluation; Failure; Fibrosis; Goals; Human Resources; Image; Imaging Techniques; Inflammation; Lung; Lung diseases; Magnetic Resonance Imaging; Measurement; Measures; Methods; Molecular; Myocardial; Myocardial dysfunction; Numbers; Patients; Phenotype; Proteomics; Pulmonary Hypertension; Pulmonary artery structure; Rate; Research Infrastructure; Resources; Right Ventricular Dysfunction; Right Ventricular Function; Right ventricular structure; Scleroderma; Serological; Services; Standards of Weights and Measures; Structure; Testing; Validation; Ventricular; base; design; detector; experience; mortality; novel; pressure; pulmonary arterial hypertension; pulmonary function

Right ventricular failure is the most important predictor of mortality for patients with severe pulmonary arterial hypertension (PAH). Based on the preliminary data of Projects 1, 2, and 3, patients with scleroderma-associated PAH-(SSc) have a significantly higher rate of right ventricular failure for the same levels of pulmonary artery pressures as patients with IPAH. Since the overall goal of our SCCOR is to understand the molecular mechanisms of right ventricular failure, increase the accuracy of phenotyping of patients, with severe PAH and to test novel therapies, an imaging core is central for several of the goals of this proposal. The primary functions of the Imaging Core are to provide comprehensive analysis and interpretation of multiple imaging biomarkers, and to develop and test novel imaging biomarkers. These imaging parameters will serve to (a) characterize extent and progression of right ventricular disease associated with PAH (with Projects 1,2, 3); (b) phenotype cardiovascular function to facilitate interpretation of serologic and proteomic markers in PAH (with Cores C, D and F and Projects 1, 2 and 3), and (c) develop/ test/ evaluate novel imaging biomarkers in terms of their sensitivity and their predictive potential for disease characterization (with Projects 1,2 and 3). Therefore, the Imaging Core will be involved actively in phenotype characterization, and biomarker discovery and validation. The right ventricle is negatively impacted by pulmonary disease, and deterioration in global RV structure and function have been measured previously using echocardiography, magnetic resonance imaging (MRI) and multi-detector CT (MDCT). The overall strategy of the imaging core will be to (1) provide reliable measurements of echocardiographic derived cardiac function, (2) provide reliable measurements of MRI and MDCT derived cardiac and pulmonary vascular function, and (3) implement novel imaging methods designed to measure regional myocardial dysfunction and myocardial fibrosis/ inflammation. Overall, we aim to comprehensively characterize RV status by assessing RV global function, RV regional function, pulmonary distensibility and RV fibrosis using noninvasive imaging methods.

右心室衰竭是重症肺病患者死亡的最重要预测因素 动脉高血压（PAH）。根据项目 1、2、3 的初步数据，患者 硬皮病相关的 PAH-(SSc) 的右心室衰竭发生率明显更高 IPAH 患者的肺动脉压力水平。由于我们 SCCOR 的总体目标是 了解右心室衰竭的分子机制，提高右心室衰竭表型分析的准确性 患有严重 PAH 的患者并测试新疗法，成像核心对于实现以下几个目标至关重要： 这个建议。成像核心的主要功能是提供全面的分析和 解释多种成像生物标志物，并开发和测试新型成像生物标志物。这些 成像参数将用于 (a) 表征右心室疾病的程度和进展 与 PAH 相关（与项目 1,2,3）； (b) 表型心血管功能以方便解释 PAH 中的血清学和蛋白质组标记物（核心 C、D 和 F 以及项目 1、2 和 3），以及 (c) 开发/测试/评估新型成像生物标志物的敏感性和预测潜力 用于疾病表征（项目 1,2 和 3）。因此，影像核心将积极参与 表型表征以及生物标志物发现和验证。 右心室受到肺部疾病和整体右心室结构恶化的负面影响 之前已使用超声心动图、磁共振成像 (MRI) 测量和功能 和多排 CT (MDCT)。成像核心的总体策略是（1）提供可靠的 超声心动图衍生的心脏功能测量，(2) 提供可靠的 MRI 测量 和 MDCT 得出的心肺血管功能，以及 (3) 实施新颖的成像方法 旨在测量局部心肌功能障碍和心肌纤维化/炎症。总的来说，我们 旨在通过评估 RV 整体功能、RV 区域功能、 使用无创成像方法观察肺扩张和右心室纤维化。